Inhibit cancer cells growth with rucaparib, a poly ADP ribose polymerase (PARP) inhibitor (PARP1 Ki < 5 nM; Thomas et al.). Highly potent and cell-permeable, rucaparib inhibits PARP in cancer cells with BRCA1 or BRCA2 mutations (Musella et al.). Activated by DNA breaks, PARP promotes repair of DNA damage through the relaxation of chromatin and recruitment of other repair proteins. Rucaparib inhibits this activity, which leads to DNA damage and death of cancer cells (Javle & Curtin ). In addition to PARP1, rucaparib also inhibits PARP2, 3, 4, 12, 15, and 16, as well as tankyrase 1 and 2 (Musella et al.).
Rucaparib has been used for:
CANCER RESEARCH
· Antagonizes multidrug resistance (MDR) in doxorubicin and paclitaxel resistance cervical cancer cell lines by binding to the active site of ATP-binding cassette (ABC) transporters (Chen et al.).
· Cytotoxic to human cell lines with mutated BRCA1/2 (MDA-MB-436, HCC1937 and CAPAN-1) and to UACC3199 cells with epigenetically silenced BRCA1 but not to cell lines without BRCA1/2 mutations (MCF7, MDA-MB-231, HCC1937-BRCA1 and OSEC-2) or heterozygous for BRCA2 mutation (OSEC-1) (Drewet al.).
· Reduces growth of mouse xenograft tumors with BRCA1/2 mutations or with epigenetically silenced BRCA1 (Drew et al.).
· Concentration-dependent antiproliferative effects in many ovarian cancer cell lines with and without BRCA1/2 mutations (Ihnen et al.).
Rucaparib has been used for:
CANCER RESEARCH
· Antagonizes multidrug resistance (MDR) in doxorubicin and paclitaxel resistance cervical cancer cell lines by binding to the active site of ATP-binding cassette (ABC) transporters (Chen et al.).
· Cytotoxic to human cell lines with mutated BRCA1/2 (MDA-MB-436, HCC1937 and CAPAN-1) and to UACC3199 cells with epigenetically silenced BRCA1 but not to cell lines without BRCA1/2 mutations (MCF7, MDA-MB-231, HCC1937-BRCA1 and OSEC-2) or heterozygous for BRCA2 mutation (OSEC-1) (Drewet al.).
· Reduces growth of mouse xenograft tumors with BRCA1/2 mutations or with epigenetically silenced BRCA1 (Drew et al.).
· Concentration-dependent antiproliferative effects in many ovarian cancer cell lines with and without BRCA1/2 mutations (Ihnen et al.).
未找到
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
Rucaparib
Catalog #
100-1168
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Rucaparib
Catalog #
100-1168
Lot #
All
Language
English
未找到
Resources and Publications
Educational Materials (3)
Request Pricing
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
欢迎您关注STEMCELL Technologies的微信公众平台
扫描二维码或搜索微信号STEMCELLTech，即可关注我们的微信平台，第一时间接收丰富的技术资源和最新的活动信息。
如您有任何问题，欢迎发消息给STEMCELLTech微信公众平台，或与我们通过电话/邮件联系：400 885 9050 INFO.CN@STEMCELL.COM。